drugset / Trial / NCT07406828

Psilocybin After Trauma Surgery for Pain

NCT07406828

Phase 1 Not yet recruiting 70 enrolled Trent Emerick The Beckwith Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are: 1. Is a single psilocybin dose feasible to administer during postoperative hospitalization? 2. Is psilocybin safe in this patient population? 3. How does psilocybin affect postoperative pain, opioid use, anxiety, and depression after hospital discharge? Participants will: Receive one oral dose of psilocybin during their postoperative inpatient stay Complete assessments of pain, mood, and opioid use during recovery

Timeline

Start
2026-07
Primary completion
2027-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 10 mg Oral

Indications

No indication recorded.